Skip to main content
. 2016 Nov 23;8(1):999–1006. doi: 10.18632/oncotarget.13533

Figure 3. Patients with tumors demonstrating MKI67 expression ≥75th percentile have shorter median survival than patients with tumors demonstrating lower MKI67 expression (16 vs 20 months, P = 0.026).

Figure 3